Trial · NCT03336216
Results by group152
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 152
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) by BICR | Arm A: Investigator Choice | 3.52 | 95% Confidence Interval 2.53 to 4.21 | Months | |
| Progression Free Survival (PFS) by BICR | Arm B: Cabiralizumab + Nivolumab | 1.92 | 95% Confidence Interval 1.77 to 2.14 | Months | |
| Progression Free Survival (PFS) by BICR | Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy | 3.68 | 95% Confidence Interval 1.94 to 4.83 | Months | |
| Progression Free Survival (PFS) by BICR | Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy | 3.22 | 95% Confidence Interval 2.04 to 3.94 | Months | |
| Progression Free Survival (PFS) by Investigator | Arm A: Investigator Choice | 3.38 | 95% Confidence Interval 1.97 to 3.98 | Months | |
| Progression Free Survival (PFS) by Investigator | Arm B: Cabiralizumab + Nivolumab | 1.81 | 95% Confidence Interval 1.74 to 1.97 | Months | |
| Progression Free Survival (PFS) by Investigator | Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy | 3.68 | 95% Confidence Interval 2.00 to 4.17 | Months | |
| Progression Free Survival (PFS) by Investigator | Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy | 2.92 | 95% Confidence Interval 1.81 to 3.94 | Months | |
| Progression Free Survival Rate (PFSR) by BICR | Arm A: Investigator Choice | 6-MONTH | 15.5 | 95% Confidence Interval 4.8 to 31.8 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm B: Cabiralizumab + Nivolumab | 6-MONTH | 13.1 | 95% Confidence Interval 5.3 to 24.4 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy | 6-MONTH | 21.7 | 95% Confidence Interval 10.5 to 35.4 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy | 6-MONTH | 17.7 | 95% Confidence Interval 7.8 to 30.8 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm A: Investigator Choice | 9-MONTH | 5.2 | 95% Confidence Interval 0.4 to 20.3 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm B: Cabiralizumab + Nivolumab | 9-MONTH | 6.5 | 95% Confidence Interval 1.7 to 16.1 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy | 9-MONTH | 9.5 | 95% Confidence Interval 2.6 to 21.8 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy | 9-MONTH | 10.1 | 95% Confidence Interval 3.2 to 21.7 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm A: Investigator Choice | 12-MONTH | NA | 95% Confidence Interval NA to NA | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm B: Cabiralizumab + Nivolumab | 12-MONTH | 2.2 | 95% Confidence Interval 0.2 to 10.0 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm C: Cabiralizumab + Nivolumab + Gemcitabine-Based Chemotherapy | 12-MONTH | 3.2 | 95% Confidence Interval 0.3 to 13.6 | Percentage of participants |
| Progression Free Survival Rate (PFSR) by BICR | Arm D: Cabiralizumab + Nivolumab + 5-FU-Based Chemotherapy | 12-MONTH | 5.1 | 95% Confidence Interval 0.9 to 15.0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03336216/results